Anticancer efficacy of a difluorodiarylidenyl piperidone (HO-3867) in human ovarian cancer cells and tumor xenografts.

@article{Selvendiran2010AnticancerEO,
  title={Anticancer efficacy of a difluorodiarylidenyl piperidone (HO-3867) in human ovarian cancer cells and tumor xenografts.},
  author={Karuppaiyah Selvendiran and Liyue Tong and Anna Bratasz and Muthulakshmi L Kuppusamy and Shabnam Ahmed and Yazhini Ravi and Nancy J Trigg and Brian K. Rivera and T{\'a}m{\'a}s K{\'a}l{\'a}i and K{\'a}lm{\'a}n Hideg and Periannan Kuppusamy},
  journal={Molecular cancer therapeutics},
  year={2010},
  volume={9 5},
  pages={1169-79}
}
The purpose of this study was to evaluate the anticancer potency and mechanism of a novel difluorodiarylidenyl piperidone (H-4073) and its N-hydroxypyrroline modification (HO-3867) in human ovarian cancer. Studies were done using established human ovarian cancer cell lines (A2870, A2780cDDP, OV-4, SKOV3, PA-1, and OVCAR3) as well as in a murine xenograft tumor (A2780) model. Both compounds were comparably and significantly cytotoxic to A2780 cells. However, HO-3867 showed a preferential… CONTINUE READING